RH35 Antibody

What is CD35 and what are its primary functions?

CD35, also known as complement receptor 1 (CR1), is a 220-300 kDa N-glycosylated protein belonging to the regulators of complement activation (RCA) family. It serves two primary functions: (1) binding and internalization of particles and immune complexes opsonized with mannose-binding lectin (MBL) or complement components C3b, C3i, C4b, or C1q; and (2) protection of cells from complement-mediated lysis by acting as a cofactor for Factor I and inhibiting C3 and C5 convertases. The extracellular domain (ECD) of human CD35 contains 30 tandem SCR/SUSHI repeats .

Functionally, CD35 is expressed on a wide range of hematopoietic cells and plays a critical role in immune complex clearance and complement regulation. The soluble form of CD35 ECD circulates in the serum and maintains complement homeostasis .

How does the structure of CD35 antibodies relate to their specificity?

CD35 antibodies, like other monoclonal antibodies, derive their specificity from their unique binding domains that recognize epitopes on the CD35 protein. The Human CD35 Antibody (Clone #594708) recognizes the region spanning from Gln42 to Asp1971 (with a His1208Arg substitution) of the CD35 protein .

The antibody specificity is determined by:

• The complementarity-determining regions (CDRs) within the variable domains

• The three-dimensional conformation of the antibody paratope

• The accessibility of the target epitope on CD35

Unlike the Rh blood group antibodies that primarily consist of IgG with some IgM components, CD35 antibodies used in research are typically engineered to specific isotypes optimized for detection rather than complement activation .

What detection methods are commonly used with CD35 antibodies?

CD35 antibodies can be detected and utilized through several methodologies:

For example, research protocols typically employ flow cytometry with CD35 antibodies followed by fluorophore-conjugated secondary antibodies, such as Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2, to detect CD35 expression on human peripheral blood mononuclear cells (PBMCs) .

How do CD35 antibodies compare with other complement receptor antibodies in experimental systems?

CD35 antibodies differ from antibodies targeting other complement receptors in several key aspects:

• Target Specificity: While CD35 antibodies recognize complement receptor 1, they must be distinguished from antibodies targeting CD21 (CR2), which has some functional overlap but different cellular distribution and ligand preferences.

• Cross-Reactivity Considerations: Unlike some complement receptor antibodies, human CD35 antibodies require careful validation as "a mouse ortholog of human CD35 has not been described, although alternate splicing of mouse CD21/CR2 generates a protein with homology to some SCR repeats of human CD35" .

• Functional Analysis: CD35 antibodies allow researchers to investigate both the complement regulatory functions and the clearance of immune complexes, whereas antibodies against other complement receptors might focus on different aspects of the complement cascade.

• Therapeutic Potential: In research contexts exploring immunomodulation, CD35 antibodies might be compared with Rh antibodies, which have established therapeutic applications in preventing Rh sensitization through mechanisms involving IgG-mediated clearance and immune response modulation .

What are the current challenges in developing high-affinity antibodies against CD35?

Developing high-affinity antibodies against CD35 presents several challenges similar to those encountered in the development of other complex target antibodies:

• Structural Complexity: The large size (220-300 kDa) and extensive glycosylation of CD35 can mask epitopes and reduce accessibility for antibody binding.

• Isoform Diversity: Multiple isoforms of CD35 exist due to genetic polymorphisms and alternative splicing, complicating the development of broadly reactive antibodies.

• Affinity Optimization: Traditional directed evolution approaches for affinity maturation can require many iterations of mutagenesis and selection, as noted in research on other antibodies: "High-affinity antibodies are often identified through directed evolution, which may require many iterations of mutagenesis and selection to find an optimal candidate" .

Recent advances in AI-based approaches, such as the RESP pipeline described for other antibodies, offer promising methods to accelerate the identification of high-affinity CD35 antibodies: "Deep learning techniques hold the potential to accelerate this process but the existing methods cannot provide the confidence interval or uncertainty needed to assess the reliability of the predictions" .

What role do CD35 antibodies play in understanding autoimmune diseases and complement dysregulation?

CD35 antibodies serve as critical tools in investigating autoimmune conditions and complement system abnormalities:

• Biomarker Analysis: CD35 expression levels, detected via specific antibodies, may serve as biomarkers for complement activation in diseases like systemic lupus erythematosus (SLE).

• Cellular Distribution Studies: By using CD35 antibodies in conjunction with other markers (such as CD19 for B cells), researchers can map the distribution and expression levels of complement receptors across immune cell populations in health and disease .

• Functional Assessments: CD35 antibodies enable investigation of complement regulatory dysfunction in conditions where excessive complement activation contributes to pathology.

• Therapeutic Target Validation: Research using CD35 antibodies helps determine whether targeting this receptor might offer therapeutic benefits in autoimmune diseases characterized by immune complex deposition and complement activation.

This research parallels investigations into other autoantibodies such as ANA, Anti-Ro/SSA, and Anti-La/SSB, which are used in the evaluation of rheumatic conditions including Sjögren's syndrome and mixed connective tissue diseases .

What validation steps are essential before using CD35 antibodies in research applications?

Before employing CD35 antibodies in research, comprehensive validation is essential:

• Specificity Testing:

  • Western blot analysis to confirm molecular weight

  • Blocking peptide competition assays

  • Testing on CD35-deficient cell lines as negative controls

  • Cross-reactivity assessment with related proteins

• Application-Specific Validation:

  • For flow cytometry: Titration experiments to determine optimal concentration

  • For immunohistochemistry: Tissue-specific fixation optimization

  • For functional studies: Confirmation that antibody binding doesn't alter receptor function unless intended

• Lot-to-Lot Consistency:

  • Comparison between different manufacturing lots

  • Standardization against reference samples

• Storage and Stability Verification:

  • Testing antibody performance after various storage conditions

  • Following manufacturer recommendations: "12 months from date of receipt, -20 to -70°C as supplied; 1 month, 2 to 8°C under sterile conditions after reconstitution; 6 months, -20 to -70°C under sterile conditions after reconstitution" .

How should researchers design experiments to study CD35 expression and function using antibodies?

Effective experimental design for CD35 research requires careful consideration of several factors:

• Control Selection:

  • Positive controls: Cells known to express CD35 (e.g., certain PBMC populations)

  • Negative controls: CD35-negative cell lines or isotype controls

  • As noted in flow cytometry protocols: "Quadrant markers were set based on control antibody staining"

• Multiparametric Analysis:

  • Co-staining with lineage markers (e.g., CD19 for B cells) to identify specific cell populations expressing CD35

  • Inclusion of viability dyes to exclude dead cells

• Functional Assays:

  • Complement regulation assays to assess CD35 function

  • Phagocytosis assays for immune complex clearance

  • Blocking studies using anti-CD35 antibodies to determine functional relevance

• Quantitative Approaches:

  • Standardization using calibration beads for flow cytometry

  • Receptor quantification using saturating concentrations of antibodies

  • Implementation of appropriate statistical analyses

The experimental design should include dilution optimization: "Optimal dilutions should be determined by each laboratory for each application" .

What are the optimal protocols for using CD35 antibodies in flow cytometry?

A standardized protocol for CD35 detection in flow cytometry includes:

Materials Required:

• Human CD35 Monoclonal Antibody

• Appropriate fluorophore-conjugated secondary antibody

• Cell wash buffer (PBS with 2% FBS)

• Fixation buffer (2% paraformaldehyde in PBS)

• Flow cytometer with appropriate laser and filter configurations

Procedure:

• Harvest cells and adjust to 1×10^6 cells/100 μL in wash buffer

• Add primary CD35 antibody at the pre-determined optimal concentration

• Incubate for 30 minutes at 4°C

• Wash cells twice with wash buffer

• Add fluorophore-conjugated secondary antibody

• Incubate for 30 minutes at 4°C in the dark

• Wash cells twice with wash buffer

• Resuspend in fixation buffer or analyze immediately

• Set appropriate gating strategies based on isotype controls

Analysis Considerations:

• For multicolor panels: "Human peripheral blood lymphocytes (PBMC) were stained with Human CD35 Monoclonal Antibody followed by Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2 Secondary Antibody and Human CD19 PE-conjugated Monoclonal Antibody"

• Compensation controls should be included when multiple fluorophores are used

• Quadrant markers should be set based on control antibody staining

How can researchers effectively use CD35 antibodies in immunohistochemical applications?

For optimal immunohistochemical detection of CD35:

Tissue Preparation:

• Fix tissues in 10% neutral buffered formalin or other appropriate fixative

• Process, embed in paraffin, and section at 4-6 μm thickness

• Deparaffinize and rehydrate sections

• Perform antigen retrieval (method should be optimized based on tissue type)

Staining Protocol:

• Block endogenous peroxidase activity (if using HRP detection)

• Perform protein blocking to reduce non-specific binding

• Apply primary CD35 antibody at optimized dilution

• Incubate overnight at 4°C or as determined in optimization studies

• Wash thoroughly

• Apply appropriate detection system (e.g., polymer-based or ABC method)

• Develop with chromogen

• Counterstain, dehydrate, and mount

Controls and Validation:

• Include positive control tissues known to express CD35

• Include negative controls (omission of primary antibody)

• Use isotype controls to assess non-specific binding

• Consider dual staining with lineage markers for colocalization studies

What techniques can improve the specificity and sensitivity of CD35 antibody-based assays?

To enhance the performance of CD35 antibody-based assays:

• Signal Amplification Strategies:

  • Tyramide signal amplification for immunohistochemistry

  • Quantum dots or polymeric detection systems

  • Proximity ligation assays for protein interaction studies

• Background Reduction Techniques:

  • Optimization of blocking buffers (species-specific serums or commercial blockers)

  • Extended washing steps with detergent-containing buffers

  • Pre-absorption of secondary antibodies with tissue homogenates

• Epitope Accessibility Enhancement:

  • Multiple antigen retrieval method comparison (heat-induced vs. enzymatic)

  • Detergent inclusion during antibody incubation

  • Optimization of fixation protocols to preserve epitope conformation

• Assay Validation Methods:

  • Peptide competition assays

  • siRNA knockdown of CD35 as negative controls

  • Parallel detection using antibodies targeting different epitopes

For flow cytometry applications specifically, researchers should "avoid repeated freeze-thaw cycles" of antibody preparations to maintain optimal activity .

What statistical approaches are recommended for analyzing CD35 antibody binding data?

Robust statistical analysis of CD35 antibody binding data requires several considerations:

How should researchers interpret changes in CD35 expression detected by antibody labeling?

Interpretation of CD35 expression changes requires careful consideration of biological and technical factors:

• Biological Context Considerations:

  • Cell type-specific baseline expression levels

  • Physiological variations due to activation state

  • Potential shedding or internalization of CD35 under certain conditions

  • Regulation by inflammatory mediators and cytokines

• Technical Interpretation Frameworks:

  • Distinguish between changes in per-cell expression (MFI) versus changes in percentage of positive cells

  • Consider changes in receptor accessibility versus actual expression changes

  • Correlation with functional assays to determine biological significance

  • Comparison with other complement regulatory proteins

• Common Pitfalls to Avoid:

  • Misinterpreting receptor modulation (internalization/recycling) as changes in expression

  • Failing to account for changes in cell populations within heterogeneous samples

  • Overinterpreting small statistically significant changes without biological significance

  • Ignoring potential effects of sample processing on epitope detection

What are the best practices for visualizing CD35 antibody binding data in scientific publications?

Effective visualization of CD35 antibody binding data enhances research communication:

• Flow Cytometry Data Presentation:

  • Overlay histograms for single-parameter comparisons

  • Contour or density plots for two-parameter analyses

  • Include gating strategies and percentages in each quadrant

  • Use consistent scaling across comparable plots

• Immunohistochemistry Image Guidelines:

  • Include scale bars on all micrographs

  • Show representative images at multiple magnifications

  • Present both overview and high-magnification images

  • Include appropriate controls for comparison

• Quantitative Data Visualization:

  • Box plots showing median, quartiles, and outliers

  • Violin plots when distribution information is important

  • Bar graphs with individual data points overlaid

  • Heat maps for multiparametric analyses

• Integrated Data Presentation:

  • Correlation plots linking expression with functional outcomes

  • Multiple panel figures showing complementary detection methods

  • Tables summarizing statistical analyses alongside graphical data

  • Schematic diagrams illustrating proposed mechanisms

What are common issues encountered when using CD35 antibodies and how can they be resolved?

Researchers frequently encounter these challenges when working with CD35 antibodies:

How can researchers distinguish between specific and non-specific binding of CD35 antibodies?

Differentiating specific from non-specific binding requires multiple validation approaches:

• Critical Controls:

  • Isotype controls matching the primary antibody's class and species

  • Blocking peptide competition assays

  • CD35-negative tissues or cells as biological negative controls

  • Secondary antibody-only controls to assess direct binding

• Analytical Approaches:

  • Dose-response curves to demonstrate saturation kinetics

  • Multiple antibodies targeting different CD35 epitopes showing similar patterns

  • Correlation between protein and mRNA expression

  • Genetic approaches (knockout/knockdown) to confirm specificity

• Technical Considerations:

  • Optimization of detergent concentration in buffers

  • Pre-adsorption of antibodies with non-specific proteins

  • Use of specialized blocking reagents for problematic tissues

  • Fc receptor blocking when working with cells expressing FcRs

What alternative approaches can complement or validate CD35 antibody-based detection methods?

To strengthen CD35 research findings, consider these complementary approaches:

• Molecular Techniques:

  • qRT-PCR for CD35 mRNA expression

  • In situ hybridization for tissue localization of mRNA

  • CRISPR/Cas9 genome editing to create CD35 knockout controls

  • Reporter gene assays for CD35 promoter activity

• Protein-Based Methods:

  • Mass spectrometry for protein identification and quantification

  • Surface plasmon resonance for binding kinetics

  • Proximity ligation assays for protein interactions

  • Western blotting for total protein expression

• Functional Assays:

  • Complement-dependent cytotoxicity assays

  • C3b/C4b binding assays

  • Immune complex clearance measurements

  • Factor I cofactor activity assessments

• Advanced Imaging:

  • Super-resolution microscopy for detailed localization

  • Live-cell imaging with fluorescently tagged CD35

  • Correlative light and electron microscopy

  • Multiplexed ion beam imaging for simultaneous detection of multiple markers

This multi-modal approach provides stronger evidence than antibody-based detection alone and can help validate findings when antibody specificity is questioned.

How might AI-based approaches enhance CD35 antibody development and application?

Artificial intelligence technologies show promise for revolutionizing CD35 antibody research:

• Enhanced Antibody Discovery:

  • Deep learning models like RESP can "accelerate this process" of identifying high-affinity antibodies by developing "a variational Bayesian neural network to perform ordinal regression" on binding data

  • AI can expand "the search space to uncover the best sequences for experimental evaluation" beyond traditional directed evolution libraries

• Improved Data Analysis:

  • Machine learning algorithms for automated gating in flow cytometry

  • Computer vision approaches for quantitative immunohistochemistry

  • Natural language processing to extract CD35-related findings from literature

• Predictive Applications:

  • Prediction of antibody binding sites based on protein structure

  • Forecasting antibody stability and manufacturing characteristics

  • Modeling of antibody-antigen interactions for improved specificity

As demonstrated with other antibodies, AI approaches like the RESP pipeline have achieved "a 17-fold improvement in the KD" of antibodies through computational modeling .

What recent methodological advances may improve CD35 antibody-based research?

Several technological developments are enhancing antibody-based research applicable to CD35 studies:

• Single-Cell Technologies:

  • Mass cytometry (CyTOF) for high-dimensional protein profiling

  • Single-cell RNA-seq with protein detection (CITE-seq)

  • Microfluidic approaches for single-cell antibody secretion analysis

• Spatially Resolved Methods:

  • Multiplexed immunofluorescence with spectral unmixing

  • Imaging mass cytometry for tissue analysis

  • Digital spatial profiling for region-specific quantification

• Antibody Engineering Approaches:

  • Site-specific conjugation for improved reporter attachment

  • Recombinant antibody fragments with enhanced tissue penetration

  • Bispecific antibodies for simultaneous targeting of CD35 and other markers

• Validation Technologies:

  • CRISPR screens for target validation

  • Proximity-dependent biotinylation for interaction partners

  • Optogenetic approaches for dynamic CD35 function studies

These advances parallel developments in other antibody fields where "learned representation trained on over 3 million human B-cell receptor sequences" has enhanced antibody development .